News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CEVEC and Catalent Pharma Solutions Offer Joint Cell Line Development Service


6/16/2011 10:50:47 AM

Cologne, Germany, June 16, 2011 / B3C newswire / – CEVEC Pharmaceuticals, the German developer of a novel, market leading human protein expression system derived from amniocytes, and Catalent Pharma Solutions, a leading global drug development and delivery solutions provider, announced today a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines the benefits of CEVEC’s human cell line, CAP-Technology, with Catalent’s unique GPEx® (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.

“We are very pleased to be working with Catalent and their truly unique technology to generate stable lines“ said Dr. Rainer Lichtenberger, CEO of CEVEC. “Several months of testing convincingly showed combining CAP cells and GPEx technology is a very powerful approach. We achieved yields exceeding 3 g/L for a very complex protein produced in our human production cell lines in a very short time frame” added Wolfgang Kintzel, Managing Director and CCO of CEVEC. “The combined offering is a very compelling value proposition for clients looking to outsource cell line development and potential downstream cGMP upscaling while looking for the highest quality using a human cell line.”

“Catalent has been collaborating with customers and suppliers to accelerate biologics development for more than ten years. This exciting collaboration with CEVEC will offer biotech companies developing recombinant proteins and antibodies the advantage of two technologies in one system, enabling them to get a clone candidate in less than 5 months and significantly reducing their time to clinic” stated Scott Houlton, President, Development & Clinical Services. “The GPEx technology has been used to express more than 380 different molecules and our integrated development and manufacturing services allow us to take our customers through their clinical trials in the fastest, most cost effective manner.”

For more information regarding GPEx® technology and Catalent’s biologics offering, please visit Catalent’s web site at www.catalent.com.

About Catalent Pharma Solutions

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 8,000 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ, USA.

Catalent. more products. better treatments. reliably supplied.™

About CEVEC Pharmaceuticals GmbH

CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work, they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP ® and CAP-T® expression systems are ideal for manufacturing complex and difficult to express biopharmaceutical molecules with authentic human glycosylation patterns. CEVEC´s CAP technology is becoming also the gold standard for various vaccines production approaches. The immortalized cells are derived from primary human amniocytes and meet highest ethical standards. Already adapted to serum-free growth conditions, they can be very efficiently transfected with commercially available transfection reagents and are optimized to grow in a variety of flask/wave formats up to large-scale processing in bioreactors. CAP® and CAP-T® are trademarks of CEVEC Pharmaceuticals GmbH, all rights reserved, CAP-T® not yet registered in all territories.

Contact

Wolfgang Kintzel

CCO / Geschäftsführer

CEVEC Pharmaceuticals GmbH

Gottfried-Hagen Straße 62

D-51105 Köln

Germany

Tel. : +49 (0) 221-46 02 08 - 00

Fax: +49 (0) 221-46 02 08 - 01

kintzel@cevec.com

Sven Lee

VP Business Development Biologics

Catalent Pharma Solutions

8137 Forsythia St

Middleton, WI 53562

USA

Tel: +1 303-841-3923

sven.lee@catalent.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES